Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Affymax Anticipates Broad Opportunity For Omontys With Both Small And Large Dialysis Providers

Executive Summary

With FDA’s March 27 approval of peginesatide to prevent anemia in CKD patients on dialysis, Affymax will focus initially on marketing to smaller, price-conscious dialysis providers. But the biotech also expects to do business with Fresenius and, to a lesser degree, Davita.

You may also be interested in...



Fresenius News Not All Bad For Affymax’s Omontys

Affymax investors were not pleased with the country’s largest dialysis provider pausing its pilot program of Omontys, but Affymax and analysts are bullish on prospects of a long-term contract developing.

Affymax Gets A Gift From Investors: Time

It’s not usually the case in biotech, but investors are showing patience for Affymax as it ramps up the launch of its long-acting erythropoiesis stimulating agent Omontys. The drug has yielded nominal sales since its launch in May but Affymax’s stock is up 25% since the drug was approved March 27.

DaVita Shifts Its Business Model With HealthCare Partners Acquisition

Dialysis provider DaVita acquires one of the largest independent physician associations, HealthCare Partners, for $4.4 billion in cash and stock, as well as earn-outs.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS054334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel